Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review.
- 31 January 2019
- journal article
- Published by Intellectual Consortium of Drug Discovery and Technology Development Incorporation
- Vol. 10 (1)
- https://doi.org/10.4172/2155-9899.1000574
Abstract
This review examines some of the reasons why we don't have a vaccine against autoimmune diseases and highlights the progress that has been made. Many autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS) and type 1 diabetes (T1D), are driven by autoimmune T cell responses. Unlike vaccines for most infectious diseases, which elicit antibody responses, are intended for immuno-naive individuals and considered preventative, a vaccine for an autoimmune disease must be therapeutic and resolve or control the on-going autoimmune response and condition in the diseased host. Despite these differences, many of the same considerations for infectious disease vaccines must also be addressed to develop a therapeutic vaccine for autoimmune diseases. The disease initiator/triggers, antigens and autoantigens, nature of the immunopathogenic and protective/therapeutic immune response will be compared for infectious and autoimmune diseases as will approaches for developing vaccines including formulations, animal models and indicators of success. The rationale for a therapeutic vaccine for RA will be discussed in greater detail with a relatively limited discussion of T1D, MS and other autoimmune diseases.This publication has 100 references indexed in Scilit:
- Molecular Mimicry as a Mechanism of Autoimmune DiseaseClinical Reviews in Allergy & Immunology, 2011
- MDSC in autoimmunityInternational Immunopharmacology, 2011
- Clinical Applications of DNA Vaccines: Current ProgressClinical Infectious Diseases, 2011
- Proteoglycan‐induced arthritis and recombinant human proteoglycan aggrecan G1 domain–induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritisArthritis & Rheumatism, 2011
- Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environmentProceedings of the National Academy of Sciences of the United States of America, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapyJournal of Autoimmunity, 2009
- Mouse models for Type 1 DiabetesDrug Discovery Today: Disease Models, 2009
- L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heartInternational Immunopharmacology, 2008
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector categoryThe Journal of Experimental Medicine, 2008